Last updated on October 2018

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1)


Brief description of study

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea), in subjects with neovascular AMD.

Detailed Study Description

A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The trial includes a screening period of less than or equal to 14 days, followed by a treatment period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.

Clinical Study Identifier: NCT03577899

Find a site near you

Start Over

Kanghong Investigative Site

Phoenix, AZ United States
  Connect »

Kanghong Investigative Site

Long Beach, CA United States
  Connect »

Kanghong Investigative Site

Pasadena, CA United States
  Connect »

Kanghong Investigative Site

Jacksonville, FL United States
  Connect »

Kanghong Investigative Site

Sarasota, FL United States
  Connect »

Kanghong Investigative Site

Grand Rapids, MI United States
  Connect »

Kanghong Investigative Site

Asheville, NC United States
  Connect »

Kanghong Investigative Site

Cleveland, OH United States
  Connect »

Kanghong Investigative Site

Houston, TX United States
  Connect »

Kanghong Investigative Site

San Antonio, TX United States
  Connect »